The receptor-toxin-antibody interaction: Mathematical model and numerical simulation [PDF]
arXiv, 2012 A reaction-diffusion model of receptor-toxin-antibody (RTA) interaction is studied numerically. The protective properties of an antibody against a given toxin are evaluated for a spherical cell placed into a toxin-antibody solution. The selection of parameters for numerical simulation approximately corresponds to the practically relevant values ...
arxiv
Fc receptors for IgG (Fc gamma Rs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the Fc gamma R. [PDF]
, 1991 Ruth I. Connor +5 more
openalex +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.All biotherapeutics have the potential to induce an immunogenic response and generate anti‐drug antibodies (ADAs), especially when administered as multiple doses over prolonged periods. However, a clinically meaningful effect of ADAs can be difficult to identify to communicate the impact of immunogenicity on drug exposure, safety and efficacy outcomes ...
Susan Richards +13 more
wiley +1 more source
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
Clinical Pharmacology &Therapeutics, EarlyView.The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou +6 more
wiley +1 more source
AntibodiesBispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong +5 more
doaj +1 more source
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody [PDF]
, 1997 Frank Hartmann +7 more
openalex +1 more source
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
Clinical Pharmacology &Therapeutics, EarlyView.Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu +12 more
wiley +1 more source
Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytes [PDF]
, 1995 C. B. H. W. Lamers +4 more
openalex +1 more source
European Journal of Heart Failure, EarlyView.Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis. Clonal haematopoiesis and heart failure: a meta‐analysis. CH, clonal haematopoiesis; CI, confidence interval; HF, heart failure. [Correction added on 15 March 2025, after first online publication: The graphical image was corrected in ...
Paschalis Karakasis +8 more
wiley +1 more source
FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy [PDF]
, 1997 Thomas Valerius +10 more
openalex +1 more source